

# Tuberculosis profile: Ghana

Population 2019: 30 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	44 000 (21 000-74 000)	144 (70-244)
HIV-positive TB incidence	9 200 (4 500-16 000)	30 (15-52)
MDR/RR-TB incidence**	1 200 (580-2 100)	4 (1.9-6.9)
HIV-negative TB mortality	10 000 (4 600-18 000)	34 (15-59)
HIV-positive TB mortality	5 000 (2 400-8 500)	16 (7.9-28)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	2.6% (2.3-2.9)
Previously treated cases	5.9% (4.2-8.1)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	34% (20-69)
TB patients facing catastrophic total costs, 2016	64% (61-68)
TB case fatality ratio (estimated mortality/estimated incidence), 2019	38% (14-67)

## TB case notifications, 2019

Total new and relapse	14 691
- % tested with rapid diagnostics at time of diagnosis	100%
- % with known HIV status	85%
- % pulmonary	92%
- % bacteriologically confirmed ^	69%
- % children aged 0-14 years	6%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	30%
- % men	64%
Total cases notified	15 063

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	2 620	21%
- on antiretroviral therapy	1 966	75%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	266
Patients started on treatment - MDR/RR-TB ^^	217
Laboratory-confirmed cases - XDR-TB ^^	2
Patients started on treatment - XDR-TB ^^	2
MDR/RR-TB cases tested for resistance to any fluoroquinolone	117

## Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	84%	13 801
Previously treated cases, excluding relapse, registered in 2018	87%	413
HIV-positive TB cases registered in 2018	77%	2 504
MDR/RR-TB cases started on second-line treatment in 2017	63%	112
XDR-TB cases started on second-line treatment in 2017		0

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	4.1%
---	------



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	0.46% (0.42-0.5)
---	---------------------

## TB financing

National TB budget, 2020 (US\$ millions)	20
- Funding source, domestic	31%
- Funding source, international	37%
- unfunded	32%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

---

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)